#VisualAbstract: Rituximab plus lenalidomide shows comparable survival compared to chemotherapy for CD20⁺ follicular lymphoma
Click to read this study in the Journal of Clinical Oncology.
Tag: B-cell lymphoma
Lisocabtagene maraleucel improves survival for relapsed or refractory large B-cell lymphoma
1. Median event-free survival in the liso-cel group was significantly greater than in the standard-of-care group (10.1 months vs. 2.3 ...
Second-line tisagenlecleucel does not improve outcomes in B-cell lymphoma
1. Patients with B-cell non-Hodgkin's lymphoma receiving tisagenlecleucel did not show delayed lymphoma progression compared to those receiving standard salvage ...
Axicabtagene ciloleucel improves event-free survival in relapsed or refractory large B-cell lymphoma
1. Patients with large B-cell lymphoma refractory to first-line therapy receiving axicabtagene ciloleucel (axi-cel) showed improvement in event-free survival compared ...
Epcoritamab shows promising response rates seen in relapsed or refractory non-Hodgkin lymphoma
1. Full-dose regimens of 48-60 mg achieved clinically significant response rates varying from 68-100%. 2. No dose-limiting toxic effects were ...
